Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MOF Urges Full Annual Price Cuts, “At Least Stepwise Reductions” in Adjustment Rate
April 14, 2022
- LDP Pharma Study Group Kicks Off Honebuto Debate, Wants Off-Year Price Cuts Scrapped
April 14, 2022
- Japan Can Get Refund on AstraZeneca Vaccine Cancellation: Minister
April 14, 2022
- Amicus Skips April Listing of MPS VII Therapy Mepsevii
April 14, 2022
- BMS’ CAR-T Therapy Abecma to Join NHI Price List on April 20
April 13, 2022
- Enhertu to Get 2.2% Price Cut in July under CEA Scheme
April 13, 2022
- Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
- Shionogi COVID Pill Doesn’t Meet “Presumed Efficacy” Criteria: HSC Subcommittee Chair
April 13, 2022
- Experts Urge AI Use for Biologics Development, Medical Data Utilization by Drug Makers: Panel
April 12, 2022
- 1st Case of Omicron XE Variant Confirmed in Japan
April 12, 2022
- Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- It’s Time to Look at Supply Status, NHI-Market Price Gap to Revisit Drug Pricing: MHLW Official
April 11, 2022
- Generic Rates at Innovative Drug Makers Hovers at 60% Range: MHLW Data
April 11, 2022
- MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- Extension of Emergency Approval Period Would Be Allowed Only Once: MHLW Official
April 7, 2022
- Moderna, Daiichi Sankyo Give mRNA Vaccine Updates: LDP Meeting
April 7, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- MHLW Lays Out CDx Requirements for Use with Multiple Drugs
April 6, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…